Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Dec;36(12):2847–2849. doi: 10.1128/aac.36.12.2847

Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli isolated in Sweden: a 10-year follow-up report.

E Sjögren 1, B Kaijser 1, M Werner 1
PMCID: PMC245558  PMID: 1482158

Abstract

Resistance to erythromycin and doxycycline and more recently to fluoroquinolones has been reported to occur in Campylobacter spp. both in vitro and in patients treated with these antibiotics. The frequency of resistance to 14 antimicrobial agents in Campylobacter jejuni and Campylobacter coli isolated from patients infected in Sweden or abroad is described. For some agents, a comparison of susceptibility in strains of Campylobacter spp. isolated in 1978 with those isolated in 1988 is made. No general increase in in vitro resistance to antibiotics commonly used for the treatment of human gastroenteritis caused by C. jejuni or C. coli has occurred during the last 10 years in Sweden, which might be a consequence of strict antibiotic control. The numbers of strains from 1988 to 1989 resistant to ciprofloxacin and to norfloxacin included in this study (0.7 and 1.4%, respectively) are still fewer than those that were resistant to erythromycin (7.3%) or doxycycline (12.4%). There is, however, since 1989 to 1990 an indication of increasing resistance to these antibiotics.

Full text

PDF
2847

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. A revised system for antibiotic sensitivity testing. The Swedish Reference Group for Antibiotics. Scand J Infect Dis. 1981;13(2):148–152. doi: 10.3109/inf.1981.13.issue-2.13. [DOI] [PubMed] [Google Scholar]
  2. Brooks B. W., Garcia M. M., Fraser D. E., Lior H., Stewart R. B., Lammerding A. M. Isolation and characterization of cephalothin-susceptible Campylobacter coli from slaughter cattle. J Clin Microbiol. 1986 Oct;24(4):591–595. doi: 10.1128/jcm.24.4.591-595.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Crumplin G. C. Mechanisms of resistance to the 4-quinolone antibacterial agents. J Antimicrob Chemother. 1990 Dec;26 (Suppl F):131–144. doi: 10.1093/jac/26.suppl_f.131. [DOI] [PubMed] [Google Scholar]
  4. Endtz H. P., Ruijs G. J., van Klingeren B., Jansen W. H., van der Reyden T., Mouton R. P. Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J Antimicrob Chemother. 1991 Feb;27(2):199–208. doi: 10.1093/jac/27.2.199. [DOI] [PubMed] [Google Scholar]
  5. Figueroa G., Troncoso M., Galeno H., Soto V., Toledo M. S. Biotypes, serogroups and antibiotic susceptibility of Campylobacter jejuni and Campylobacter coli in Chile. J Infect. 1990 Mar;20(2):123–127. doi: 10.1016/0163-4453(90)93314-i. [DOI] [PubMed] [Google Scholar]
  6. Goodman L. J., Fliegelman R. M., Trenholme G. M., Kaplan R. L. Comparative in vitro activity of ciprofloxacin against Campylobacter spp. and other bacterial enteric pathogens. Antimicrob Agents Chemother. 1984 Apr;25(4):504–506. doi: 10.1128/aac.25.4.504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Goossens H., De Mol P., Coignau H., Levy J., Grados O., Ghysels G., Innocent H., Butzler J. P. Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens. Antimicrob Agents Chemother. 1985 Mar;27(3):388–392. doi: 10.1128/aac.27.3.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gootz T. D., Martin B. A. Characterization of high-level quinolone resistance in Campylobacter jejuni. Antimicrob Agents Chemother. 1991 May;35(5):840–845. doi: 10.1128/aac.35.5.840. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Harvey S. M. Hippurate hydrolysis by Campylobacter fetus. J Clin Microbiol. 1980 Apr;11(4):435–437. doi: 10.1128/jcm.11.4.435-437.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. McNulty C. A. The treatment of campylobacter infections in man. J Antimicrob Chemother. 1987 Mar;19(3):281–284. doi: 10.1093/jac/19.3.281. [DOI] [PubMed] [Google Scholar]
  11. Michel J., Rogol M., Dickman D. Susceptibility of clinical isolates of Campylobacter jejuni to sixteen antimicrobial agents. Antimicrob Agents Chemother. 1983 May;23(5):796–797. doi: 10.1128/aac.23.5.796. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Rademaker C. M., Hoepelman I. M., Wolfhagen M. J., Beumer H., Rozenberg-Arska M., Verhoef J. Results of a double-blind placebo-controlled study using ciprofloxacin for prevention of travelers' diarrhea. Eur J Clin Microbiol Infect Dis. 1989 Aug;8(8):690–694. doi: 10.1007/BF01963753. [DOI] [PubMed] [Google Scholar]
  13. Skirrow M. B. Campylobacter enteritis: a "new" disease. Br Med J. 1977 Jul 2;2(6078):9–11. doi: 10.1136/bmj.2.6078.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Svedhem A., Kaijser B., Sjögren E. Antimicrobial susceptibility of Campylobacter jejuni isolated from humans with diarrhoea and from healthy chickens. J Antimicrob Chemother. 1981 Mar;7(3):301–305. doi: 10.1093/jac/7.3.301. [DOI] [PubMed] [Google Scholar]
  15. Taylor D. E., Courvalin P. Mechanisms of antibiotic resistance in Campylobacter species. Antimicrob Agents Chemother. 1988 Aug;32(8):1107–1112. doi: 10.1128/aac.32.8.1107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Taylor D. E., Ng L. K., Lior H. Susceptibility of Campylobacter species to nalidixic acid, enoxacin, and other DNA gyrase inhibitors. Antimicrob Agents Chemother. 1985 Nov;28(5):708–710. doi: 10.1128/aac.28.5.708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Taylor D. N., Blaser M. J., Echeverria P., Pitarangsi C., Bodhidatta L., Wang W. L. Erythromycin-resistant Campylobacter infections in Thailand. Antimicrob Agents Chemother. 1987 Mar;31(3):438–442. doi: 10.1128/aac.31.3.438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Tenover F. C., Williams S., Gordon K. P., Nolan C., Plorde J. J. Survey of plasmids and resistance factors in Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother. 1985 Jan;27(1):37–41. doi: 10.1128/aac.27.1.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wang W. L., Reller L. B., Blaser M. J. Comparison of antimicrobial susceptibility patterns of Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother. 1984 Sep;26(3):351–353. doi: 10.1128/aac.26.3.351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Williams M. D., Schorling J. B., Barrett L. J., Dudley S. M., Orgel I., Koch W. C., Shields D. S., Thorson S. M., Lohr J. A., Guerrant R. L. Early treatment of Campylobacter jejuni enteritis. Antimicrob Agents Chemother. 1989 Feb;33(2):248–250. doi: 10.1128/aac.33.2.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Wiström J., Norrby S. R., Burman L. G., Lundholm R., Jellheden B., Englund G. Norfloxacin versus placebo for prophylaxis against travellers' diarrhoea. J Antimicrob Chemother. 1987 Oct;20(4):563–574. doi: 10.1093/jac/20.4.563. [DOI] [PubMed] [Google Scholar]
  22. Yan W., Taylor D. E. Characterization of erythromycin resistance in Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother. 1991 Oct;35(10):1989–1996. doi: 10.1128/aac.35.10.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES